ArticleJournal of virology2005
Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Therapeutic Approaches of Viral Gene Silencing by Small Interfering RNA: Strategies to Prevent the Emergence of Antiviral Resistant Escape Mutants.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Are Viral Vectors Any Good for RNAi Antiviral Therapy?Viruses · 2020Article
- Viral Vectors Applied for RNAi-Based Antiviral Therapy.Viruses · 2020Review
- An efficient method for multigene co-interference by recombinant Bombyx mori nucleopolyhedrovirus.Molecular genetics and genomics : MGG · 2019Article
- Kinetic Modeling of Virus Growth in Cells.Microbiology and molecular biology reviews : MMBR · 2018Review
- Microbial control of arthropod-borne disease.Memorias do Instituto Oswaldo Cruz · 2017Review
- Efficacy Analysis of Combinatorial siRNAs against HIV Derived from One Double Hairpin RNA Precursor.Frontiers in microbiology · 2017Article
- Article
- The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Silencing of HIV-1 gag gene from epidemic strains among men who have sex with men (MSM) in Tianjin, China by a broad-spectrum short hairpin RNA.Virusdisease · 2014Article
- The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA.Nucleic acids research · 2013Article
- Fluctuations in Tat copy number when it counts the most: a possible mechanism to battle the HIV latency.Theoretical biology & medical modelling · 2013Article
- Preclinical evaluation of an anti-HCV miRNA cluster for treatment of HCV infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Selection of RNAi-based inhibitors for anti-HIV gene therapy.World journal of virology · 2012Review
- HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Antiviral RNAi: translating science towards therapeutic success.Pharmaceutical research · 2011Review
- A comparison of multiple shRNA expression methods for combinatorial RNAi.Genetic vaccines and therapy · 2011Article
- Multiple shRNA combinations for near-complete coverage of all HIV-1 strains.AIDS research and therapy · 2011Article
- In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.Retrovirology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently developed antiviral strategies based upon RNA interference (RNAi), which harnesses an innate cellular system for the targeted down-regulation of gene expression, appear highly promising and offer alternative approaches to conventional highly active antiretroviral therapy or efforts to develop an AIDS vaccine. However, RNAi is faced with several challenges that must be overcome to fully realize its promise. Specifically, it degrades target RNA in a highly sequence-specific manner and is thus susceptible to viral mutational escape, and there are also challenges in delivery systems to induce RNAi. To aid in the development of anti-human immunodeficiency virus (anti-HIV) RNAi therapies, we have developed a novel stochastic computational model that simulates in molecular-level detail the propagation of an HIV infection in cells expressing RNAi. The model provides quantitative predictions on how targeting multiple locations in the HIV genome, while keeping the overall RNAi strength constant, significantly improves efficacy. Furthermore, it demonstrates that delivery systems must be highly efficient to preclude leaving reservoirs of unprotected cells where the virus can propagate, mutate, and eventually overwhelm the entire system. It also predicts how therapeutic success depends upon a relationship between RNAi strength and delivery efficiency and uniformity. Finally, targeting an essential viral element, in this case the HIV TAR region, can be highly successful if the RNAi target sequence is correctly selected. In addition to providing specific predictions for how to optimize a clinical therapy, this system may also serve as a future tool for investigating more fundamental questions of viral evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.